ArticleVaccine2013
Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.
Article in Vaccine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- COMBO-RATE: An experimentally validated bioinformatic tool to identify promiscuous HLA restrictions.bioRxiv : the preprint server for biology · 2026Article
- Characterization of Duffy Binding Protein II-specific CD4Scientific reports · 2023Article
- Inhibition of a malaria host-pathogen interaction by a computationally designed inhibitor.Protein science : a publication of the Protein Society · 2023Article
- Article
- Review
- Progress towards the development of aExpert review of vaccines · 2021Review
- Article
- Genetic diversity in two Plasmodium vivax protein ligands for reticulocyte invasion.PLoS neglected tropical diseases · 2018Article
- Identification and Immunological Characterization of the Ligand Domain of Plasmodium vivax Reticulocyte Binding Protein 1a.The Journal of infectious diseases · 2018Article
- Persistence of Long-lived Memory B Cells specific to Duffy Binding Protein in individuals exposed to Plasmodium vivax.Scientific reports · 2018Article
- An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies.Scientific reports · 2017Article
- The Molecular Basis of Erythrocyte Invasion by Malaria Parasites.Cell host & microbe · 2017Review
- Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Natural acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein (PvDBP-II) equally block erythrocyte binding of homologous and heterologous expressed PvDBP-II on the surface of COS-7 cells.Medical microbiology and immunology · 2016Article
- The role of the human Duffy antigen receptor for chemokines in malaria susceptibility: current opinions and future treatment prospects.Journal of receptor, ligand and channel research · 2016Article
- Strain-Transcending Inhibitory Antibodies against Homologous and Heterologous Strains of Duffy Binding Protein region II.PloS one · 2016Article
- Structural analysis of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for Plasmodium vivax malaria vaccine design.PLoS neglected tropical diseases · 2015Article
- Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.Clinical and vaccine immunology : CVI · 2014Article
- The Duffy binding protein as a key target for a Plasmodium vivax vaccine: lessons from the Brazilian Amazon.Memorias do Instituto Oswaldo Cruz · 2014Review
- Strategies for designing and monitoring malaria vaccines targeting diverse antigens.Frontiers in immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The Duffy binding protein (DBP) of Plasmodium vivax is vital for host erythrocyte invasion. DBP region II (DBPII) contains critical residues for receptor recognition and anti-DBPII antibodies have been shown to inhibit erythrocyte binding and invasion, thereby making the molecule an attractive vaccine candidate against P. vivax blood stages. Similar to other blood-stage antigens, allelic variation within the DBPII and associated strain-specific immunity is a major challenge for development of a broadly effective vaccine against P. vivax malaria. We hypothesized that immunization with a vaccine composed of multiple DBP alleles or a modified epitope DBP (DEKnull) will be more effective in producing a broadly reactive and inhibitory antibody response to diverse DBPII alleles than a single allele vaccine. In this study, we compared single, naturally occurring DBPII allele immunizations (Sal1, 7.18, P) and DEKnull with a combination of (Sal1, 7.18, P) alleles. Quantitative analysis by ELISA demonstrated that the multiple allele vaccine tend to be more immunogenic than any of the single allele vaccines when tested for reactivity against a panel of DBPII allelic variants whereas DEKnull was less immunogenic than the mixed-allele vaccine but similar in reactivity to the single allele vaccines. Further analysis for functional efficacy by in vitro erythrocyte-binding inhibition assays demonstrated that the multiple allele immunization produced a stronger strain-neutralizing response than the other vaccination strategies even though inhibition remained biased toward some alleles. Overall, there was no correlation between antibody titer and functional inhibition. These data suggest that a multiple allele vaccine may enhance immunogenicity of a DBPII vaccine but further investigation is required to optimize this vaccine strategy to achieve broader coverage against global P. vivax strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.